Isothiazole dioxides as CXC- and CC-chemokine receptor ligands

US7671212B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Arthur G. Taveras · Rockaway, US
• J. Merritt · Ewing, US
• John J. Baldwin · Gwynedd Valley, US
• Junying Zheng · New Providence, US
• Purakkattle Biju · Piscataway, US
• Younong Yu · East Brunswick Township, US
• Jianhua Chao · Pompton Lakes, US
• Gaifa Lai · Edison, US
• Minglang Wu · Monmouth Junction, US

Key dates

• Filing date: Dec 20, 2004
• Grant date: Mar 2, 2010
• Expiry date: Feb 27, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel compounds of the formula:and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.